Carotuximab
Carotuximab was an antibody against endoglin, a protein on growing blood vessels and on angiosarcoma cells. Added to pazopanib in the phase 3 TAPPAS trial it did not help, and the trial was stopped in 2019.
Overview
Carotuximab (TRC105) was Tracon Pharmaceuticals' antibody against endoglin, a marker of angiogenic endothelium and of angiosarcoma, a cancer that arises from blood vessel lining. Endoglin signalling was thought to be one way tumours escape VEGF blockade, so the antibody was combined with VEGFR inhibitors. Early-phase results in angiosarcoma with pazopanib were encouraging.
The randomised phase 3 TAPPAS trial of pazopanib with or without carotuximab in advanced angiosarcoma was stopped in 2019 after an interim analysis showed no improvement in progression-free survival, and the programme ended. The angiosarcoma page lists it with bevacizumab added to paclitaxel (ANGIOTAX-PLUS) among the antiangiogenic additions that failed.
Binds endoglin (CD105), a TGF-beta co-receptor highly expressed on proliferating tumour endothelium and on angiosarcoma cells, to block a vessel-growth pathway that escapes VEGF inhibition.
1.Carotuximab binds its target.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Carotuximab" OR ABSTRACT:"Carotuximab" OR TITLE:"TRC105" OR ABSTRACT:"TRC105") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Carotuximab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCediranib
Shares Pazopanib and the tag subtype-drugs-wave.
- TreatmentLenzilumab
Shares Monoclonal antibodies and the tag subtype-drugs-wave.
- TreatmentINCA033989
Shares Monoclonal antibodies and the tag subtype-drugs-wave.
- TreatmentEnvafolimab
- CancerEpithelioid haemangioendothelioma
Shares Angiosarcoma, Pazopanib.
- CancerVascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)
Shares Angiosarcoma, Pazopanib.